SCHEDULE: Cingulate Secures $11M Investment, Board Seats for Investors

Cingulate Inc. announced an $11 million private placement of common stock, preferred stock, and warrants, granting significant ownership and board representation to Falcon Creek and Ginkgo Capital.

Summary

• Cingulate Inc. completed a private placement totaling $11,006,002.42.
• The investment involved the sale of common stock, Series A convertible preferred stock, and warrants to purchase common stock.
• Initial purchasers were Castlehouse VCC Harvest Win and Falcon Creek Technology Fund I.
• Castlehouse VCC Harvest Win subsequently assigned its purchase rights to Ginkgo Capital Global Fund SPC Xtalpi AI Fund SP.
• Ginkgo Capital Global Fund SPC acquired 1,757,393 shares of Common Stock, 973 shares of Series A Preferred Stock (Stated Value $1,000/share, Conversion Price $5.04/share), and warrants for 1,556,420 Common Stock shares for $10,006,000.00.
• Falcon Creek Technology Fund I acquired 194,553 shares of Common Stock and warrants for 155,642 Common Stock shares for $1,000,002.42.
• The Reporting Persons (Falcon Creek Capital Advisor, Falcon Creek Technology Fund I, and Ginkgo Capital Global Fund SPC) collectively beneficially own approximately 19.99% of Cingulate's outstanding Common Stock, totaling 2,073,957 shares.
• Stockholder approval is required for the conversion of preferred stock and for warrant exercises exceeding the 19.99% beneficial ownership threshold.
• The company will file a registration statement for the resale of these securities within 60 days of closing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as Cingulate Inc. has successfully secured significant capital from institutional investors, which is vital for its operational continuity and growth, despite the inherent dilution for existing shareholders.

Positives

• Cingulate Inc. secured over $11 million in new capital through a private placement, strengthening its financial position.
• The investment includes a commitment to board representation for the investors, suggesting a long-term strategic alignment.
• The company will file a registration statement for the resale of the securities, providing liquidity pathways for the investors.

Negatives

• The issuance of new shares and convertible securities will result in dilution for existing shareholders, which could be substantial under certain market conditions.
• Stockholder approval is required for full conversion of preferred stock and exercise of warrants beyond a 19.99% ownership threshold, introducing a potential delay or uncertainty for investors to fully realize their ownership.
• The lock-up period of 180 days restricts the investors' ability to sell their securities immediately.

Risks

• Dilution of outstanding Common Stock for existing shareholders, potentially substantial under certain market conditions.
• Failure to obtain stockholder approval could limit the conversion of preferred stock and the exercise of warrants beyond the 19.99% threshold, impacting investors' full realization of their ownership.
• The company's ability to maintain its listing on a Trading Market and comply with listing requirements.
• Potential for adverse effects from litigation, labor disputes, environmental non-compliance, or regulatory actions (FDA, Anti-Corruption, Export Control, Customs, CFIUS, Money Laundering Laws) if not managed effectively, as stated in the company's general representations and warranties.
• The company's financial condition and ability to meet its debts as they mature, although the filing states assets exceed liabilities and capital is sufficient.

Future Outlook

The company is obligated to seek stockholder approval for the full conversion of preferred stock and exercise of warrants beyond a 19.99% beneficial ownership threshold. It also plans to file a registration statement for the resale of the newly issued securities within 60 days of closing and use commercially reasonable efforts to have it declared effective.

Management Comments

• The undersigned, Cingulate Inc., a Delaware corporation, hereby acknowledge the partial assignment of the Agreement as contemplated by the foregoing Assignment and Assumption of Agreement.

Industry Context

StockSavvy.ai notes that this private placement by Cingulate Inc. aligns with a common strategy for smaller biotechnology or pharmaceutical companies to raise capital from institutional investors to fund ongoing research, development, and operational needs. The inclusion of board representation and observer rights for the investors suggests a deeper strategic partnership beyond a simple capital injection, potentially indicating investor confidence in the company's long-term prospects and a desire for active oversight. The structured nature of the investment, involving common stock, preferred stock, and warrants, is typical for such deals, offering investors a blend of immediate equity, convertible upside, and potential for future participation.

Comparison to Industry Standards

• The investment structure, combining common stock, convertible preferred stock, and warrants, is a standard approach in private placements for growth-stage companies, similar to deals seen with biotech firms like Moderna (MRNA) in its early funding rounds or BioNTech (BNTX) before its IPO, where institutional investors often seek structured instruments offering both downside protection and upside potential.
• The 19.99% beneficial ownership cap before stockholder approval is a common regulatory threshold (e.g., Nasdaq Rule 5635) to avoid triggering immediate shareholder approval requirements for significant equity issuances, a practice observed across many publicly traded companies raising capital.
• The provision for board representation (up to two directors) and an observer seat is typical for significant institutional investments, comparable to arrangements made by venture capital or private equity firms in companies like CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT) during their growth phases, where active investor involvement in governance is sought.
• The 180-day lock-up period for investors is a standard industry practice to prevent immediate selling pressure on the stock post-transaction, similar to lock-up agreements in IPOs or follow-on offerings for companies like Beam Therapeutics (BEAM) or Intellia Therapeutics (NTLA).

Management Changes

Corporate Governance

Legal Proceedings

• None of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) in the last 5 years.
• None of the Reporting Persons have been party to a civil proceeding resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting/mandating activities subject to, federal or state securities laws in the last 5 years.
• The company represents that there is no pending or threatened action, suit, inquiry, notice of violation, proceeding, or investigation against or affecting the Company or its Subsidiaries that could result in a Material Adverse Effect, except as set forth in SEC Reports.

Related Party Transactions

• The Authorization Agreement between Falcon Creek Capital Advisor, LLC (Investment Manager) and Ginkgo Capital Co., Limited (Fund Manager for Ginkgo Capital Global Fund SPC Xtalpi AI Fund SP) details the delegation of investment management activities for the Sub-Fund's investment in Cingulate Inc.
• Zhanpeng Jiang is listed as Partner for Assignor (Castlehouse VCC Harvest Win) and Managing Partner for Assignee (Falcon Creek Capital Global Fund SPC Xtalpi AI Fund SP, via its Investment Manager Falcon Creek Capital Advisor, LLC) on the Assignment and Assumption Agreement, and also signs the Schedule 13D for all three Reporting Persons, indicating a common individual managing multiple entities involved in the transaction.

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of new shares and convertible securities. However, the capital infusion could support company growth, potentially benefiting long-term shareholders. Stockholder approval is required for full conversion/exercise beyond 19.99%, giving existing shareholders a vote on significant future dilution.
• Company (Cingulate Inc.): Receives over $11 million in capital for general corporate and working capital purposes, strengthening its financial position and supporting its business operations. Gains strategic input from new board members/observers.
• Investors (Falcon Creek, Ginkgo Capital): Acquire significant equity and convertible instruments in Cingulate Inc., along with board representation and observer rights, providing influence and oversight over their investment.

Next Steps

• Cingulate Inc. must seek stockholder approval for the full conversion of preferred stock and exercise of warrants beyond the 19.99% beneficial ownership threshold.
• The company is required to file a registration statement for the resale of the issued securities within 60 days following the closing date.
• The company will use commercially reasonable efforts to have the registration statement declared effective within 90 days of filing.
• Falcon Creek Capital Advisor will designate one director to the Board of Directors on the closing date and a second director after stockholder approval is obtained.
• Ginkgo Capital Global Fund SPC will designate one non-voting observer to the Board of Directors until stockholder approval is obtained.

Key Dates

Recommendation

The capital raise is a positive for Cingulate Inc., providing necessary funding for operations and growth. However, the immediate dilution and the requirement for future stockholder approval for full conversion/exercise introduce some uncertainty. The lock-up and standstill provisions suggest a long-term investment horizon from the new investors. Given these factors, a 'hold' recommendation is appropriate, allowing investors to observe the company's utilization of the new capital and the outcome of the stockholder approval process before making further investment decisions.

Keywords

Cingulate Inc., Private Placement, Securities Purchase Agreement, Common Stock, Preferred Stock, Warrants, Capital Raise, Institutional Investment, Falcon Creek Capital Advisor, Ginkgo Capital Global Fund, Schedule 13D, Beneficial Ownership, Corporate Governance, Board Representation, Dilution, Lock-up, Standstill Agreement, SEC Filing